

Anti-Amyloid Beta Antibody (Aducanumab)

Introduction

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid beta (A β). Aducanumab exhibits brain penetration and can be used in Alzheimer's disease (AD) research.

Product parameters

Alternative Names	Aduhelm, BIIB037, BART
Target Accession	P05067
Target	Amyloid Beta
CAS number	1384260-65-4
Molecular Weight	146.2 kDa
Host	CHO
Reactivity	Human, Mouse, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized N His HSA human Amyloid beta(APP) at 2 ug/mL can bind Anti-Amyloid Beta Antibody (Aducanumab), EC50=0.9454 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

